Drugs / SAR440234
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03594955 | Oct 2018 → Feb 2021 | leukemia | Sanofi | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR440234 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03594955 ↗ |
| Route | Intravenous | “Route of administration: intravenous” NCT03594955 ↗ |